Identifying Concerns in Arizona with the Inclusion of the Indication or Reason for Use on the Prescription through Focus Groups
dc.contributor.advisor | Warholak, Terri | en |
dc.contributor.advisor | Rupp, Michael T. | en |
dc.contributor.author | Skulkan, Kaitlyn | |
dc.contributor.author | Warholak, Terri | |
dc.contributor.author | Rupp, Michael T. | |
dc.date.accessioned | 2016-06-21T22:00:44Z | |
dc.date.available | 2016-06-21T22:00:44Z | |
dc.date.issued | 2016 | |
dc.identifier.uri | http://hdl.handle.net/10150/614017 | |
dc.description | Class of 2016 Abstract | en |
dc.description.abstract | Objectives: To identify stakeholder concerns regarding a potential requirement that all prescriptions include the reason for use or indication. Methods: This was a mixed methods study that employed focus groups. Participants were invited by the Chief Executive Officer (CEO) of the Arizona Pharmacy Association (AzPA) to attend focus groups via webinar. E-mail invites were sent to AzPA members and members of Arizona healthcare professional associations with prescriptive authority except for prescribers who care for animals. The discussion began with a PowerPoint presentation and then questions were presented to guide discussion. Afterwards, questionnaires were distributed through e-mail. Interval level data were analyzed using means and standard deviations. The commentary of the focus group discussion was summarized in themes. Results: Preliminary findings, from two focus groups with a total of seven participants, reflected the following concerns with the inclusion of the indication on prescriptions: compromise of patient privacy; technology capabilities; prescriber time; prescriber compliance; and prior authorization complications. The proposed benefits were: enhanced communication; better medication counseling; reduced prescribing errors; decreased controlled substance diversion; and increased accuracy of a prospective drug use review by pharmacists for patients with complicated disease states. Conclusions: In conclusion, stakeholders were concerned with the implementation of including the indication on prescription orders. | |
dc.language.iso | en_US | en |
dc.publisher | The University of Arizona. | en |
dc.rights | Copyright © is held by the author. | en |
dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | |
dc.subject | Arizona | en |
dc.subject | Arizona Pharmacy Association (AzPA) | en |
dc.subject | Focus Groups | en |
dc.subject | Indication | en |
dc.subject | Prescription | en |
dc.subject.mesh | Prescriptions | |
dc.title | Identifying Concerns in Arizona with the Inclusion of the Indication or Reason for Use on the Prescription through Focus Groups | en_US |
dc.type | text | en |
dc.type | Electronic Report | en |
dc.contributor.department | College of Pharmacy, The University of Arizona | en |
dc.description.collectioninformation | This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu. | en |
html.description.abstract | Objectives: To identify stakeholder concerns regarding a potential requirement that all prescriptions include the reason for use or indication. Methods: This was a mixed methods study that employed focus groups. Participants were invited by the Chief Executive Officer (CEO) of the Arizona Pharmacy Association (AzPA) to attend focus groups via webinar. E-mail invites were sent to AzPA members and members of Arizona healthcare professional associations with prescriptive authority except for prescribers who care for animals. The discussion began with a PowerPoint presentation and then questions were presented to guide discussion. Afterwards, questionnaires were distributed through e-mail. Interval level data were analyzed using means and standard deviations. The commentary of the focus group discussion was summarized in themes. Results: Preliminary findings, from two focus groups with a total of seven participants, reflected the following concerns with the inclusion of the indication on prescriptions: compromise of patient privacy; technology capabilities; prescriber time; prescriber compliance; and prior authorization complications. The proposed benefits were: enhanced communication; better medication counseling; reduced prescribing errors; decreased controlled substance diversion; and increased accuracy of a prospective drug use review by pharmacists for patients with complicated disease states. Conclusions: In conclusion, stakeholders were concerned with the implementation of including the indication on prescription orders. |